PW_C000086
HMDB0000132:
View Metabocard
|
Guanine
Guanine is one of the five main nucleobases found in the nucleic acids DNA and RNA. Guanine is a derivative of purine, consisting of a fused pyrimidine-imidazole ring system with conjugated double bonds. Being unsaturated, the bicyclic molecule is planar. The guanine nucleoside is called guanosine. The first isolation of guanine was reported in 1844 from the excreta of sea birds, known as guano, which was used as a source of fertilizer. High affinity binding of guanine nucleotides and the ability to hydrolyze bound GTP to GDP are characteristics of an extended family of intracellular proteins. Guanine nucleotide-binding regulatory proteins may be involved in the activation of phospholipases C and A2 by hormones and other ligands. The binding of hormones to receptors that activate phospholipase C is decreased by guanine nucleotides and these hormones also stimulate a high-affinity GTPase activity in cell membranes. Effects of hormones on phospholipase C activity in cell-free preparations are dependent on the presence of guanine nucleotides. Hypoxanthine-guanine phosphoribosyltransferase (HPRT, EC 2.4.2.8) is a purine salvage enzyme that catalyses the conversion of hypoxanthine and guanine to their respective mononucleotides. Partial deficiency of this enzyme can result in the overproduction of uric acid leading to a severe form of gout, whilst a virtual absence of HPRT activity causes the Lesch-Nyhan syndrome which is characterised by hyperuricaemia, mental retardation, choreoathetosis and compulsive self-mutilation. Peroxynitrite induces DNA base damage predominantly at guanine (G) and 8-oxoguanine (8-oxoG) nucleobases via oxidation reactions. G and 8-oxoG are the most reactive bases toward Peroxynitrite and possibly the major contributors to peroxynitrite-derived genotoxic and mutagenic lesions. The neutral G radical, reacts with NO2 to yield 8-nitroguanine and 5-nitro-4-guanidinohydantoin. (PMID: 16352449, 2435586, 2838362, 1487231).
|
Drug Metabolism Drug Action
|
|
PW_C000087
HMDB0000133:
View Metabocard
|
Guanosine
Guanosine is a nucleoside comprising guanine attached to a ribose (ribofuranose) ring via a beta-N9-glycosidic bond. Guanosine can be phosphorylated to become GMP (guanosine monophosphate), cGMP (cyclic guanosine monophosphate), GDP (guanosine diphosphate), and GTP (guanosine triphosphate) (Wikipedia). This nucleoside exerts important neuroprotective and neuromodulator roles in the central nervous system, which may be related to inhibition of the glutamatergic neurotransmission activity. Guanosine is the specific extracellular guanine-based purines effector and its conversion occurs not only in the central nervous system but also peripherally (PMID: 16325434). Guanosine is found to be associated with purine nucleoside phosphorylase (PNP) deficiency, which is an inborn error of metabolism.
|
Drug Metabolism Drug Action
|
|
PW_C000088
HMDB0000134:
View Metabocard
|
Fumaric acid
Fumaric acid is a precursor to L-malate in the Krebs tricarboxylic acid cycle. It is formed by the oxidation of succinate by succinate dehydrogenase. Fumarate is converted by fumarase to malate. A fumarate is a salt or ester of the organic compound fumaric acid, a dicarboxylic acid. (wikipedia).
|
Drug Metabolism Drug Action
|
|
PW_C000089
HMDB0000138:
View Metabocard
|
Glycocholic acid
Glycocholic acid is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID:16949895 ). More specifically, glycocholic acid or cholylglycine, is a crystalline bile acid involved in the emulsification of fats. It occurs as a sodium salt in the bile of mammals. Its anion is called glycocholate. As the glycine conjugate of cholic acid, this compound acts as a detergent to solubilize fats for absorption and is itself absorbed. (PubChem). Bile acids are steroid acids found predominantly in bile of mammals. The distinction between different bile acids is minute, depends only on presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g., membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues. (PMID: 11316487 , 16037564 , 12576301 , 11907135 ).
|
Drug Metabolism Drug Action
|
|
PW_C000090
HMDB0000139:
View Metabocard
|
Glyceric acid
Glyceric acid is a colourless syrupy acid, obtained from oxidation of glycerol. It is a compound that is secreted excessively in the urine by patients suffering from D-glyceric aciduria, an inborn error of metabolism, and D-glycerate anemia. Deficiency of human glycerate kinase leads to D-glycerate acidemia/D-glyceric aciduria. Symptoms of the disease include progressive neurological impairment, hypotonia, seizures, failure to thrive, and metabolic acidosis. At sufficiently high levels, glyceric acid can act as an acidogen and a metabotoxin. An acidogen is an acidic compound that induces acidosis, which has multiple adverse effects on many organ systems. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Glyceric acid is an organic acid. Abnormally high levels of organic acids in the blood (organic acidemia), urine (organic aciduria), the brain, and other tissues lead to general metabolic acidosis. Acidosis typically occurs when arterial pH falls below 7.35. In infants with acidosis, the initial symptoms include poor feeding, vomiting, loss of appetite, weak muscle tone (hypotonia), and lack of energy (lethargy). These can progress to heart abnormalities, seizures, coma, and possibly death. These are also the characteristic symptoms of untreated glyceric aciduria. Many affected children with organic acidemias experience intellectual disability or delayed development. In adults, acidosis or acidemia is characterized by headaches, confusion, feeling tired, tremors, sleepiness, and seizures.
|
Metabolic
|
|
PW_C000092
HMDB0000142:
View Metabocard
|
Formic acid
Formic acid is the simplest carboxylic acid. Formate is an intermediate in normal metabolism. It takes part in the metabolism of one-carbon compounds and its carbon may appear in methyl groups undergoing transmethylation. It is eventually oxidized to carbon dioxide. Formate is typically produced as a byproduct in the production of acetate. It is responsible for both metabolic acidosis and disrupting mitochondrial electron transport and energy production by inhibiting cytochrome oxidase activity, the terminal electron acceptor of the electron transport chain. Cell death from cytochrome oxidase inhibition by formate is believed to result partly from depletion of ATP, reducing energy concentrations so that essential cell functions cannot be maintained. Furthermore, inhibition of cytochrome oxidase by formate may also cause cell death by increased production of cytotoxic reactive oxygen species (ROS) secondary to the blockade of the electron transport chain. In nature, formic acid is found in the stings and bites of many insects of the order Hymenoptera, including bees and ants. The principal use of formic acid is as a preservative and antibacterial agent in livestock feed. When sprayed on fresh hay or other silage, it arrests certain decay processes and causes the feed to retain its nutritive value longer.
|
Drug Metabolism Drug Action
|
|
PW_C000093
HMDB0000143:
View Metabocard
|
D-Galactose
D-Galactose is an aldohexose that occurs naturally in the D-form in lactose, cerebrosides, gangliosides, and mucoproteins. D-Galactose is an energy-providing nutrient and also a necessary basic substrate for the biosynthesis of many macromolecules in the body. Metabolic pathways for D-Galactose are important not only for the provision of these pathways but also for the prevention of D-Galactose and D-Galactose metabolite accumulation. The main source of D-Galactose is lactose in the milk of mammals, but it can also be found in some fruits and vegetables. Utilization of D-Galactose in all living cells is initiated by the phosphorylation of the hexose by the enzyme galactokinase (E.C. 2.7.1.6) (GALK) to form D-Galactose-1-phosphate. In the presence of D-Galactose-1-phosphate uridyltransferase (E.C. 2.7.7.12) (GALT) D-Galactose-1-phosphate is exchanged with glucose-1-phosphate in UDP-glucose to form UDP-galactose. Glucose-1-phosphate will then enter the glycolytic pathway for energy production. Deficiency of the enzyme GALT in galactosemic patients leads to the accumulation of D-Galactose-1-phosphate. Classic galactosemia-a term that denotes the presence of D-Galactose in the blood is the rare inborn error of D-Galactose metabolism, diagnosed by the deficiency of the second enzyme of the D-Galactose assimilation pathway, GALT, which, in turn, is caused by mutations at the GALT gene. (PMID: 15256214, 11020650, 10408771).
|
Metabolic
|
|
PW_C000094
HMDB0000145:
View Metabocard
|
Estrone
Estrone is a major mammalian estrogen. The conversion of the natural C19 steroids, testosterone and androstenedione into estrone is dependent on a complex key reaction catalyzed by the cytochrome P450 aromatase (EC 1.14.14.1, unspecific monooxygenase), which is expressed in many tissues of the adult human (e.g. ovary, fat tissue), but not in the liver. The ovaries after menopause continue to produce androstenedione and testosterone in significant amounts and these androgens are converted in fat, muscle, and skin into estrone. When women between the ages of 45 and 64 years have prophylactic oophorectomy (when hysterectomy is performed for benign disease to prevent the development of ovarian cancer), evidence suggests that oophorectomy increases the subsequent risk of coronary heart disease (CHD) and osteoporosis. Whereas 14,000 women die of ovarian cancer every year nearly 490,000 women die of heart disease and 48,000 women die within 1 year after hip fracture. Therefore, the decision to perform prophylactic oophorectomy should be approached with great caution for the majority of women who are at low risk of developing ovarian cancer. Steroid sulfatase (EC 3.1.6.2, STS) hydrolyzes steroid sulfates, such as estrone sulfate to estrone which can be converted to steroids with potent estrogenic properties, that is, estradiol; STS activity is much higher in breast tumors and high levels of STS mRNA expression in tumors are associated with a poor prognosis. The biological roles of estrogens in tumorigenesis are certainly different between the endometrium and breast, although both are considered "estrogen-dependent tissues". 17beta-hydroxysteroid dehydrogenases (EC 1.1.1.62, 17-HSDs) are enzymes involved in the formation of active sex steroids. estrone is interconverted by two enzymes 17-HSD types. Type 1 converts estrone to estradiol and Type 2 catalyzes the reverse reaction. (PMID: 17653961, 17513923, 17470679, 17464097).
|
Drug Metabolism Drug Action
|
|
PW_C000095
HMDB0000148:
View Metabocard
|
L-Glutamic acid
Glutamic acid (Glu), also referred to as glutamate (the anion), is one of the 20 proteinogenic amino acids. It is not among the essential amino acids. Glutamate is a key molecule in cellular metabolism. In humans, dietary proteins are broken down by digestion into amino acids, which serves as metabolic fuel or other functional roles in the body. Glutamate is the most abundant fast excitatory neurotransmitter in the mammalian nervous system. At chemical synapses, glutamate is stored in vesicles. Nerve impulses trigger release of glutamate from the pre-synaptic cell. In the opposing post-synaptic cell, glutamate receptors, such as the NMDA receptor, bind glutamate and are activated. Because of its role in synaptic plasticity, it is believed that glutamic acid is involved in cognitive functions like learning and memory in the brain. Glutamate transporters are found in neuronal and glial membranes. They rapidly remove glutamate from the extracellular space. In brain injury or disease, they can work in reverse and excess glutamate can accumulate outside cells. This process causes calcium ions to enter cells via NMDA receptor channels, leading to neuronal damage and eventual cell death, and is called excitotoxicity. The mechanisms of cell death include: * Damage to mitochondria from excessively high intracellular Ca2+. * Glu/Ca2+-mediated promotion of transcription factors for pro-apoptotic genes, or downregulation of transcription factors for anti-apoptotic genes. Excitotoxicity due to glutamate occurs as part of the ischemic cascade and is associated with stroke and diseases like amyotrophic lateral sclerosis, lathyrism, and Alzheimer's disease. glutamic acid has been implicated in epileptic seizures. Microinjection of glutamic acid into neurons produces spontaneous depolarization around one second apart, and this firing pattern is similar to what is known as paroxysmal depolarizing shift in epileptic attacks. This change in the resting membrane potential at seizure foci could cause spontaneous opening of voltage activated calcium channels, leading to glutamic acid release and further depolarization. (http://en.wikipedia.org/wiki/Glutamic_acid).
|
Drug Metabolism Drug Action
|
- 2-Aminoadipic 2-Oxoadipic Aciduria
- 2-Aminoadipic 2-Oxoadipic Aciduria
- 2-Hydroxyglutric Aciduria (D and L Form)
- 2-Methyl-3-hydroxybutyryl-CoA Dehydrogenase Deficiency
- 2-Methyl-3-hydroxybutyryl-CoA Dehydrogenase Deficiency
- 3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency
- 3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency
- 3-Hydroxyisobutyric Acid Dehydrogenase Deficiency
- 3-Hydroxyisobutyric Acid Dehydrogenase Deficiency
- 3-Hydroxyisobutyric Aciduria
- 3-Hydroxyisobutyric Aciduria
- 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I
- 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I
- 3-Methylglutaconic Aciduria Type I
- 3-Methylglutaconic Aciduria Type I
- 3-Methylglutaconic Aciduria Type III
- 3-Methylglutaconic Aciduria Type III
- 3-Methylglutaconic Aciduria Type IV
- 3-Methylglutaconic Aciduria Type IV
- 3-Phosphoglycerate Dehydrogenase Deficiency
- 3-Phosphoglycerate Dehydrogenase Deficiency
- 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency
- 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency
- 5-Oxoprolinase Deficiency
- 5-Oxoprolinase Deficiency
- 5-Oxoprolinuria
- 5-Oxoprolinuria
- ACE
- Acetaminophen Action Pathway
- Acetylsalicylic Acid Action Pathway
- Adenine Phosphoribosyltransferase Deficiency (APRT)
- Adenine Phosphoribosyltransferase Deficiency (APRT)
- Adenosine Deaminase Deficiency
- Adenosine Deaminase Deficiency
- Adenylosuccinate Lyase Deficiency
- Adenylosuccinate Lyase Deficiency
- Aerobic Glycolysis (Warburg Effect)
- AICA-Ribosiduria
- Alanine Metabolism
- Alkaptonuria
- Alprazolam Action Pathway
- Amantadine NMDA Antagonist Action Pathway
- Amino Sugar Metabolism
- Ammonia Recycling
- Amobarbital Action Pathway
- Antipyrine Action Pathway
- Antrafenine Action Pathway
- Arachidonic Acid Metabolism
- Arginine and Proline Metabolism
- Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)
- Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)
- Argininemia
- Argininemia
- Argininosuccinic Aciduria
- Argininosuccinic Aciduria
- Aspartate Metabolism
- Azathioprine Action Pathway
- Azathioprine Action Pathway (New)
- Azilsartan medoxomil Action Pathway
- Benazepril ACE inhibitor Action Pathway
- beta-Alanine Metabolism
- beta-Aminoisobutyric Aciduria
- beta-Ketothiolase Deficiency
- beta-Ketothiolase Deficiency
- beta-Mercaptolactate-Cysteine Disulfiduria
- beta-Mercaptolactate-Cysteine Disulfiduria
- Brexanolone Action Pathway
- Bromazepam Action Pathway
- Bromfenac Action Pathway
- Butabarbital Action Pathway
- Butalbital Action Pathway
- Butobarbital Action Pathway
- Caffeine Nervous Action Pathway
- Canavan Disease
- Canavan Disease
- Candesartan Action Pathway (New)
- Candesartan cilexetil Action Pathway
- Carbamoyl Phosphate Synthetase Deficiency
- Carbamoyl Phosphate Synthetase Deficiency
- Carnosinuria, Carnosinemia
- Carnosinuria, Carnosinemia
- Carprofen Action Pathway
- Celecoxib metabolism Pathway
- Chlordiazepoxide Action Pathway
- Cilazapril ACE inhibitor Action Pathway
- Citrullinemia Type I
- Citrullinemia Type I
- Clobazam Action Pathway
- Clonazepam Action Pathway
- Clorazepic Acid Action Pathway
- Clotiazepam Action Pathway
- Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency
- Cysteine Metabolism
- Cystinosis, Ocular Nonnephropathic
- Cystinosis, Ocular Nonnephropathic
- Desflurane GABA(A) Anesthetic Action Pathway
- Dextromethorphan NMDA Antagonism Action Pathway
- Diazepam Action Pathway
- Diclofenac Action Pathway
- Diflunisal Action Pathway
- Dihydropyrimidine Dehydrogenase Deficiency (DHPD)
- Dimethylglycine Dehydrogenase Deficiency
- Dimethylglycine Dehydrogenase Deficiency
- Dimethylglycine Dehydrogenase Deficiency
- Disulfiram Action Pathway
- Dopamine beta-Hydroxylase Deficiency
- Dopamine beta-Hydroxylase Deficiency
- Enalapril ACE Inhibitor Action Pathway
- Esketamine Action Pathway
- Estazolam Action Pathway
- Eszopiclone Action Pathway
- Ethanol GABA Agonist Action Pathway
- Ethanol NMDA Antagonist Action Pathway
- Ethosuximide Action Pathway
- Etizolam Action Pathway
- Etodolac Action Pathway
- Etomidate Action Pathway
- Etoricoxib Action Pathway
- Felbamate NMDA Antagonist Action Pathway
- Fenoprofen Action Pathway
- Fimasartan Action Pathway
- Flumazenil Action Pathway
- Flunitrazepam Action Pathway
- Flurazepam Action Pathway
- Flurbiprofen Action Pathway
- Folate Malabsorption, Hereditary
- Folate Malabsorption, Hereditary
- Folate Metabolism
- Forasartan Angiotensin Blocker Action Pathway
- Fosinopril ACE Inhibitor Action Pathway
- Fospropofol Action Pathway
- GABA
- GABA-Transaminase Deficiency
- GABA-Transaminase Deficiency: beta-alanine
- Gamma-Aminobutyric Acid Biosynthesis
- gamma-Glutamyltransferase Deficiency
- gamma-Glutamyltransferase Deficiency
- gamma-Glutamyltranspeptidase Deficiency
- gamma-Glutamyltranspeptidase Deficiency
- Ganaxolone Action Pathway
- Glucose-Alanine Cycle
- Glutamate Metabolism
- Glutaminolysis and Cancer
- Glutaric Aciduria Type I
- Glutaric Aciduria Type I (Lysine Degradation)
- Glutathione Metabolism
- Glutathione Synthetase Deficiency
- Glutathione Synthetase Deficiency
- Glutethimide Action Pathway
- Glycine and Serine Metabolism
- Gout or Kelley-Seegmiller Syndrome
- Gout or Kelley-Seegmiller Syndrome
- Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)
- Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)
- Haloperidol NMDA Antagonist Action Pathway
- Halothane GABA(A) Anesthetic Action Pathway
- Halothane NMDA Antagonist Action Pathway
- Hawkinsinuria
- Hawkinsinuria
- Histidine Metabolism
- Histidinemia
- Histidinemia
- Homocarnosinosis
- Homocarnosinosis
- Hyperglycinemia, Non-Ketotic
- Hyperinsulinism-Hyperammonemia Syndrome
- Hyperinsulinism-Hyperammonemia Syndrome
- Hyperlysinemia I, Familial
- Hyperlysinemia I, Familial
- Hyperlysinemia II or Saccharopinuria
- Hyperornithinemia with Gyrate Atrophy (HOGA)
- Hyperornithinemia with Gyrate Atrophy (HOGA)
- Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH-syndrome)
- Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH-syndrome)
- Hyperprolinemia Type I
- Hyperprolinemia Type I
- Hyperprolinemia Type II
- Hyperprolinemia Type II
- Hypoacetylaspartia
- Hypoacetylaspartia
- Ibuprofen Action Pathway
- Indomethacin Action Pathway
- Irbesartan Angiotensin blocker Action Pathway
- Isobutyryl-CoA Dehydrogenase Deficiency
- Isobutyryl-CoA Dehydrogenase Deficiency
- Isoflurane GABA(A) Anesthetic Action Pathway
- Isovaleric Acidemia
- Isovaleric Acidemia
- Isovaleric Aciduria
- Isovaleric Aciduria
- Ketamine NMDA Antagonist Action Pathway
- Ketazolam Action Pathway
- Ketoprofen Action Pathway
- Ketorolac Action Pathway
- L-Arginine:Glycine Amidinotransferase Deficiency
- L-Arginine:Glycine Amidinotransferase Deficiency
- Lactic Acidemia
- Lactic Acidemia
- Lactulose Action Pathway
- Lesch-Nyhan Syndrome (LNS)
- Leukotriene C4 Synthesis Deficiency
- Levoleucovorin Action Pathway
- Lisinopril ACE Inhibitor
- Lorazepam Action Pathway
- Lormetazepam Action Pathway
- Lornoxicam Action Pathway
- Losartan Angiotensin blocker Action Pathway
- Lumiracoxib Action Pathway
- Lysine Degradation
- Magnesium Salicylate Action Pathway
- Malate-Aspartate Shuttle
- Malonic Aciduria
- Malonic Aciduria
- Malonyl-CoA Decarboxylase Deficiency
- Malonyl-CoA Decarboxylase Deficiency
- Maple Syrup Urine Disease
- Maple Syrup Urine Disease
- Mefenamic Acid Action Pathway
- Meloxicam Action Pathway
- Memantine Action Pathway
- Meprobamate Action Pathway
- Mercaptopurine Action Pathway
- Mercaptopurine Action Pathway (New)
- Metabolism and Physiological Effects of 4-Hydroxyphenylacetic acid
- Metabolism and Physiological Effects of N-alpha-Acetyl-L-arginine
- Metabolism and Physiological Effects of Oxalic acid
- Metabolism and Physiological Effects of p-Cresol sulphate
- Metabolism and Physiological Effects of Para-cresol
- Metabolism and Physiological Effects of Tiglylglycine
- Metabolsim and Physiological Effects of Argininic acid
- Methadone NMDA Antagonism Action Pathway
- Methotrexate Action Pathway
- Methotrexate Action Pathway (new)
- Methsuximide Action Pathway
- Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)
- Methylmalonate Semialdehyde Dehydrogenase Deficiency
- Methylmalonate Semialdehyde Dehydrogenase Deficiency
- Methylmalonic Aciduria
- Methylmalonic Aciduria
- Methylmalonic Aciduria Due to Cobalamin-Related Disorders
- Methylmalonic Aciduria Due to Cobalamin-Related Disorders
- Methylphenobarbital Action Pathway
- Midazolam Action Pathway
- Mitochondrial DNA Depletion Syndrome-3
- Mitochondrial DNA Depletion Syndrome-3
- Moexipril ACE Inhibitor Action Pathway
- Molybdenum Cofactor Deficiency
- Molybdenum Cofactor Deficiency
- Monoamine Oxidase-A Deficiency (MAO-A)
- Monoamine Oxidase-A Deficiency (MAO-A)
- Mycophenolic Acid Action Pathway
- Myoadenylate Deaminase Deficiency
- Myoadenylate Deaminase Deficiency
- Nabumetone Action Pathway
- Naproxen Action Pathway
- Nepafenac Action Pathway
- Nicotinate and Nicotinamide Metabolism
- Nitrazepam Action Pathway
- NMDA
- Non-Ketotic Hyperglycinemia
- Non-Ketotic Hyperglycinemia
- Olmesartan ARB Action Pathway
- Ornithine Aminotransferase Deficiency (OAT Deficiency)
- Ornithine Aminotransferase Deficiency (OAT Deficiency)
- Ornithine Transcarbamylase Deficiency (OTC Deficiency)
- Ornithine Transcarbamylase Deficiency (OTC Deficiency)
- Orphenadrine NMDA Antagonist Action Pathway
- Oxaprozin Action Pathway
- Oxazepam Action Pathway
- Pafolacianine Action Pathway
- Paramethadione Action Pathway
- Pemetrexed Action Pathway
- Pentobarbital Action Pathway
- Perindopril ACE Inhibitor Action Pathway
- Phenobarbital Action Pathway
- Phenylalanine and Tyrosine Metabolism
- Phenylbutazone Action Pathway
- Phenylketonuria
- Piroxicam Action Pathway
- Pralatrexate Action Pathway
- Prazepam Action Pathway
- Pregabalin Action Pathway
- Primary Hyperoxaluria Type I
- Primary Hyperoxaluria Type I
- Primidone Action Pathway
- Procaine NMDA Antagonist Action Pathway
- Profenamine Action Pathway
- Prolidase Deficiency (PD)
- Prolinemia Type II
- Prolinemia Type II
- Propanoate Metabolism
- Propionic Acidemia
- Propionic Acidemia
- Protein Synthesis: Glutamic Acid
- Purine Metabolism
- Purine Nucleoside Phosphorylase Deficiency
- Purine Nucleoside Phosphorylase Deficiency
- Pyridoxine Dependency with Seizures
- Pyridoxine Dependency with Seizures
- Pyruvate Carboxylase Deficiency
- Pyruvate Carboxylase Deficiency
- Quazepam Action Pathway
- Quinapril ACE Inhibitor Action Pathway
- Quinidine barbiturate Action Pathway
- Raltitrexed Action Pathway
- Ramipril ACE Inhibitor Action Pathway
- Remimazolam Action Pathway
- Rofecoxib Action Pathway
- Saccharopinuria/Hyperlysinemia II
- Saccharopinuria/Hyperlysinemia II
- Salicylate-Sodium Action Pathway
- Salicylic Acid Action Pathway
- Salla Disease/Infantile Sialic Acid Storage Disease
- Salla Disease/Infantile Sialic Acid Storage Disease
- Salsalate Action Pathway
- Saprisartan Action Pathway
- Sarcosinemia
- Sarcosinemia
- Secobarbital Action Pathway
- Sevoflurane GABA(A) Anesthetic Action Pathway
- Sialuria or French Type Sialuria
- Sialuria or French Type Sialuria
- Stiripentol GABA(A) Antiepileptic Action Pathway
- Succinic Semialdehyde Dehydrogenase Deficiency
- Sulfanilamide Action Pathway
- Sulindac Action Pathway
- Suprofen Action Pathway
- Talbutal Action Pathway
- Tasosartan Action Pathway
- Tay-Sachs Disease
- Tay-Sachs Disease
- Telmisartan Action Pathway (New)
- Temazepam Action Pathway
- Tenoxicam Action Pathway
- The Oncogenic Action of 2-Hydroxyglutarate
- The Oncogenic Action of D-2-Hydroxyglutarate in Hydroxyglutaric aciduria
- The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxyglutaric aciduria
- Thiocolchicoside Action Pathway (New)
- Thioguanine Action Pathway (old)
- Thiopental Action Pathway
- Tiaprofenic Acid Action Pathway
- Tioguanine Action Pathway
- Tizanidine
- Tolmetin Action Pathway
- Trandolapril ACE Inhibitor Action Pathway
- Triazolam Action Pathway
- Trimethadione Action Pathway
- Trisalicylate-Choline Action Pathway
- Tryptophan Metabolism
- Tyrosine Metabolism
- Tyrosinemia Type 2 (or Richner-Hanhart Syndrome)
- Tyrosinemia Type 2 (or Richner-Hanhart Syndrome)
- Tyrosinemia Type 3 (TYRO3)
- Tyrosinemia Type 3 (TYRO3)
- Tyrosinemia Type I
- Tyrosinemia Type I
- Tyrosinemia, Transient, of the Newborn
- Tyrosinemia, Transient, of the Newborn
- Urea Cycle
- Valdecoxib Action Pathway
- Valine, Leucine, and Isoleucine Degradation
- Valsartan Action Pathway (New)
- Xanthine Dehydrogenase Deficiency (Xanthinuria)
- Xanthinuria Type I
- Xanthinuria Type I
- Xanthinuria Type II
- Xanthinuria Type II
- Zaleplon Action Pathway
- Ziconotide Analgesia Action Pathway
- Ziconotide NMDA and Substance P Receptor Pain Inhibition Action Pathway
- Zofenopril Action Pathway
- Zolpidem Action Pathway (New)
- Zopiclone Action Pathway
- (
show more
show less
)
|
PW_C000096
HMDB0000149:
View Metabocard
|
Ethanolamine
Ethanolamine is a viscous, hygroscopic amino alcohol with an ammoniacal odor. It is widely distributed in biological tissue and is a component of lecithin. It is used as a surfactant, fluorometric reagent, and to remove CO2 and H2S from natural gas and other gases.
|
Drug Metabolism Drug Action
|
- Phosphatidylcholine Biosynthesis
- Phosphatidylethanolamine Biosynthesis
- Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(12Z)-2OH(9,10))
- Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(12Z)-O(9S,10R))
- Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(9Z)-O(12,13))
- Phosphatidylethanolamine Biosynthesis PE(14:0/18:2(10E,12Z)+=O(9))
- Phosphatidylethanolamine Biosynthesis PE(14:0/18:2(9Z,11E)+=O(13))
- Phosphatidylethanolamine Biosynthesis PE(14:0/18:3(10,12,15)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(14:0/18:3(9,11,15)-OH(13))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:3(5Z,11Z,14Z)-O(8,9))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:3(5Z,8Z,11Z)-O(14R,15S))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:3(5Z,8Z,14Z)-O(11S,12R))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:3(6,8,11)-OH(5))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:3(8Z,11Z,14Z)-2OH(5,6))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:3(8Z,11Z,14Z)-O(5,6))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5E,8Z,12Z,14Z)-OH(11R))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5Z,7E,11Z,14Z)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5Z,8Z,10E,14Z)-OH(12S))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5Z,8Z,11Z,13E)+=O(15))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5Z,8Z,11Z,13E)-OH(15S))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5Z,8Z,11Z,14Z)-OH(17))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5Z,8Z,11Z,14Z)-OH(20))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(6E,8Z,11Z,14Z)+=O(5))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(6E,8Z,11Z,14Z)-OH(5S))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))
- Phosphatidylethanolamine Biosynthesis PE(14:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(14:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))
- Phosphatidylethanolamine Biosynthesis PE(14:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))
- Phosphatidylethanolamine Biosynthesis PE(14:0/5-iso PGF2VI)
- Phosphatidylethanolamine Biosynthesis PE(14:0/6 keto-PGF1alpha)
- Phosphatidylethanolamine Biosynthesis PE(14:0/LTE4)
- Phosphatidylethanolamine Biosynthesis PE(14:0/PGD1)
- Phosphatidylethanolamine Biosynthesis PE(14:0/PGD2)
- Phosphatidylethanolamine Biosynthesis PE(14:0/PGE1)
- Phosphatidylethanolamine Biosynthesis PE(14:0/PGE2)
- Phosphatidylethanolamine Biosynthesis PE(14:0/PGF1alpha)
- Phosphatidylethanolamine Biosynthesis PE(14:0/PGF2alpha)
- Phosphatidylethanolamine Biosynthesis PE(14:0/PGJ2)
- Phosphatidylethanolamine Biosynthesis PE(14:0/TXB2)
- Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(12Z)-2OH(9,10))
- Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(12Z)-O(9S,10R))
- Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(9Z)-O(12,13))
- Phosphatidylethanolamine Biosynthesis PE(15:0/18:2(10E,12Z)+=O(9))
- Phosphatidylethanolamine Biosynthesis PE(15:0/18:2(9Z,11E)+=O(13))
- Phosphatidylethanolamine Biosynthesis PE(15:0/18:3(10,12,15)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(15:0/18:3(9,11,15)-OH(13))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:3(5Z,11Z,14Z)-O(8,9))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:3(5Z,8Z,11Z)-O(14R,15S))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:3(5Z,8Z,14Z)-O(11S,12R))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:3(6,8,11)-OH(5))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:3(8Z,11Z,14Z)-2OH(5,6))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:3(8Z,11Z,14Z)-O(5,6))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5E,8Z,12Z,14Z)-OH(11R))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5Z,7E,11Z,14Z)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5Z,8Z,10E,14Z)-OH(12S))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5Z,8Z,11Z,13E)+=O(15))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5Z,8Z,11Z,13E)-OH(15S))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5Z,8Z,11Z,14Z)-OH(17))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5Z,8Z,11Z,14Z)-OH(20))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(6E,8Z,11Z,14Z)+=O(5))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(6E,8Z,11Z,14Z)-OH(5S))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))
- Phosphatidylethanolamine Biosynthesis PE(15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
- Phosphatidylethanolamine Biosynthesis PE(15:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))
- Phosphatidylethanolamine Biosynthesis PE(15:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))
- Phosphatidylethanolamine Biosynthesis PE(15:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))
- Phosphatidylethanolamine Biosynthesis PE(15:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))
- Phosphatidylethanolamine Biosynthesis PE(15:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))
- Phosphatidylethanolamine Biosynthesis PE(15:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))
- Phosphatidylethanolamine Biosynthesis PE(15:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))
- Phosphatidylethanolamine Biosynthesis PE(15:0/5-iso PGF2VI)
- Phosphatidylethanolamine Biosynthesis PE(15:0/6 keto-PGF1alpha)
- Phosphatidylethanolamine Biosynthesis PE(15:0/LTE4)
- Phosphatidylethanolamine Biosynthesis PE(15:0/PGD1)
- Phosphatidylethanolamine Biosynthesis PE(15:0/PGD2)
- Phosphatidylethanolamine Biosynthesis PE(15:0/PGE1)
- Phosphatidylethanolamine Biosynthesis PE(15:0/PGE2)
- Phosphatidylethanolamine Biosynthesis PE(15:0/PGF1alpha)
- Phosphatidylethanolamine Biosynthesis PE(15:0/PGF2alpha)
- Phosphatidylethanolamine Biosynthesis PE(15:0/PGJ2)
- Phosphatidylethanolamine Biosynthesis PE(15:0/TXB2)
- Phosphatidylethanolamine Biosynthesis PE(16:0/18:1(12Z)-2OH(9,10))
- Phosphatidylethanolamine Biosynthesis PE(16:0/18:1(12Z)-O(9S,10R))
- Phosphatidylethanolamine Biosynthesis PE(16:0/18:1(9Z)-O(12,13))
- Phosphatidylethanolamine Biosynthesis PE(16:0/18:2(10E,12Z)+=O(9))
- Phosphatidylethanolamine Biosynthesis PE(16:0/18:2(9Z,11E)+=O(13))
- Phosphatidylethanolamine Biosynthesis PE(16:0/18:3(10,12,15)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(16:0/18:3(9,11,15)-OH(13))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:3(5Z,11Z,14Z)-O(8,9))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:3(5Z,8Z,11Z)-O(14R,15S))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:3(5Z,8Z,14Z)-O(11S,12R))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:3(6,8,11)-OH(5))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:3(8Z,11Z,14Z)-2OH(5,6))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:3(8Z,11Z,14Z)-O(5,6))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5E,8Z,12Z,14Z)-OH(11R))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5Z,7E,11Z,14Z)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5Z,8Z,10E,14Z)-OH(12S))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5Z,8Z,11Z,13E)+=O(15))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5Z,8Z,11Z,13E)-OH(15S))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5Z,8Z,11Z,14Z)-OH(17))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5Z,8Z,11Z,14Z)-OH(20))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(6E,8Z,11Z,14Z)+=O(5))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(6E,8Z,11Z,14Z)-OH(5S))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))
- Phosphatidylethanolamine Biosynthesis PE(16:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
- Phosphatidylethanolamine Biosynthesis PE(16:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))
- Phosphatidylethanolamine Biosynthesis PE(16:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))
- Phosphatidylethanolamine Biosynthesis PE(16:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))
- Phosphatidylethanolamine Biosynthesis PE(16:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))
- Phosphatidylethanolamine Biosynthesis PE(16:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))
- Phosphatidylethanolamine Biosynthesis PE(16:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))
- Phosphatidylethanolamine Biosynthesis PE(16:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))
- Phosphatidylethanolamine Biosynthesis PE(16:0/5-iso PGF2VI)
- Phosphatidylethanolamine Biosynthesis PE(16:0/6 keto-PGF1alpha)
- Phosphatidylethanolamine Biosynthesis PE(16:0/LTE4)
- Phosphatidylethanolamine Biosynthesis PE(16:0/PGD1)
- Phosphatidylethanolamine Biosynthesis PE(16:0/PGD2)
- Phosphatidylethanolamine Biosynthesis PE(16:0/PGE1)
- Phosphatidylethanolamine Biosynthesis PE(16:0/PGE2)
- Phosphatidylethanolamine Biosynthesis PE(16:0/PGF1alpha)
- Phosphatidylethanolamine Biosynthesis PE(16:0/PGF2alpha)
- Phosphatidylethanolamine Biosynthesis PE(16:0/PGJ2)
- Phosphatidylethanolamine Biosynthesis PE(16:0/TXB2)
- Phosphatidylethanolamine Biosynthesis PE(18:0/18:1(12Z)-2OH(9,10))
- Phosphatidylethanolamine Biosynthesis PE(18:0/18:1(12Z)-O(9S,10R))
- Phosphatidylethanolamine Biosynthesis PE(18:0/18:1(9Z)-O(12,13))
- Phosphatidylethanolamine Biosynthesis PE(18:0/18:2(10E,12Z)+=O(9))
- Phosphatidylethanolamine Biosynthesis PE(18:0/18:2(9Z,11E)+=O(13))
- Phosphatidylethanolamine Biosynthesis PE(18:0/18:3(10,12,15)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(18:0/18:3(9,11,15)-OH(13))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:3(5Z,11Z,14Z)-O(8,9))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:3(5Z,8Z,11Z)-O(14R,15S))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:3(5Z,8Z,14Z)-O(11S,12R))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:3(6,8,11)-OH(5))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:3(8Z,11Z,14Z)-2OH(5,6))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:3(8Z,11Z,14Z)-O(5,6))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5E,8Z,12Z,14Z)-OH(11R))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,7E,11Z,14Z)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,10E,14Z)-OH(12S))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,11Z,13E)+=O(15))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,11Z,13E)-OH(15S))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,11Z,14Z)-OH(17))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,11Z,14Z)-OH(20))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(6E,8Z,11Z,14Z)+=O(5))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(6E,8Z,11Z,14Z)-OH(5S))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))
- Phosphatidylethanolamine Biosynthesis PE(18:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
- Phosphatidylethanolamine Biosynthesis PE(18:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))
- Phosphatidylethanolamine Biosynthesis PE(18:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))
- Phosphatidylethanolamine Biosynthesis PE(18:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))
- Phosphatidylethanolamine Biosynthesis PE(18:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))
- Phosphatidylethanolamine Biosynthesis PE(18:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))
- Phosphatidylethanolamine Biosynthesis PE(18:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))
- Phosphatidylethanolamine Biosynthesis PE(18:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))
- Phosphatidylethanolamine Biosynthesis PE(18:0/5-iso PGF2VI)
- Phosphatidylethanolamine Biosynthesis PE(18:0/6 keto-PGF1alpha)
- Phosphatidylethanolamine Biosynthesis PE(18:0/LTE4)
- Phosphatidylethanolamine Biosynthesis PE(18:0/PGD1)
- Phosphatidylethanolamine Biosynthesis PE(18:0/PGD2)
- Phosphatidylethanolamine Biosynthesis PE(18:0/PGE1)
- Phosphatidylethanolamine Biosynthesis PE(18:0/PGE2)
- Phosphatidylethanolamine Biosynthesis PE(18:0/PGF1alpha)
- Phosphatidylethanolamine Biosynthesis PE(18:0/PGF2alpha)
- Phosphatidylethanolamine Biosynthesis PE(18:0/PGJ2)
- Phosphatidylethanolamine Biosynthesis PE(18:0/TXB2)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-2OH(9,10)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-2OH(9,10)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-2OH(9,10)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-2OH(9,10)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-2OH(9,10)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-2OH(9,10)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-O(9S,10R)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-O(9S,10R)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-O(9S,10R)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-O(9S,10R)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-O(9S,10R)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(12Z)-O(9S,10R)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)-O(12,13)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)-O(12,13)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)-O(12,13)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)-O(12,13)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)-O(12,13)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)-O(12,13)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(10E,12Z)+=O(9)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(10E,12Z)+=O(9)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(10E,12Z)+=O(9)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(10E,12Z)+=O(9)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(10E,12Z)+=O(9)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(10E,12Z)+=O(9)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,11E)+=O(13)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,11E)+=O(13)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,11E)+=O(13)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,11E)+=O(13)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,11E)+=O(13)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,11E)+=O(13)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(10,12,15)-OH(9)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(10,12,15)-OH(9)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(10,12,15)-OH(9)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(10,12,15)-OH(9)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(10,12,15)-OH(9)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(10,12,15)-OH(9)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(9,11,15)-OH(13)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(9,11,15)-OH(13)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(9,11,15)-OH(13)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(9,11,15)-OH(13)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(9,11,15)-OH(13)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(18:3(9,11,15)-OH(13)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:0/18:1(12Z)-2OH(9,10))
- Phosphatidylethanolamine Biosynthesis PE(20:0/18:1(12Z)-O(9S,10R))
- Phosphatidylethanolamine Biosynthesis PE(20:0/18:1(9Z)-O(12,13))
- Phosphatidylethanolamine Biosynthesis PE(20:0/18:2(10E,12Z)+=O(9))
- Phosphatidylethanolamine Biosynthesis PE(20:0/18:2(9Z,11E)+=O(13))
- Phosphatidylethanolamine Biosynthesis PE(20:0/18:3(10,12,15)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(20:0/18:3(9,11,15)-OH(13))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:3(5Z,11Z,14Z)-O(8,9))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:3(5Z,8Z,11Z)-O(14R,15S))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:3(5Z,8Z,14Z)-O(11S,12R))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:3(6,8,11)-OH(5))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:3(8Z,11Z,14Z)-2OH(5,6))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:3(8Z,11Z,14Z)-O(5,6))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5E,8Z,12Z,14Z)-OH(11R))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5Z,7E,11Z,14Z)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5Z,8Z,10E,14Z)-OH(12S))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5Z,8Z,11Z,13E)+=O(15))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5Z,8Z,11Z,13E)-OH(15S))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5Z,8Z,11Z,14Z)-OH(17))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5Z,8Z,11Z,14Z)-OH(20))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(6E,8Z,11Z,14Z)+=O(5))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(6E,8Z,11Z,14Z)-OH(5S))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))
- Phosphatidylethanolamine Biosynthesis PE(20:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
- Phosphatidylethanolamine Biosynthesis PE(20:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))
- Phosphatidylethanolamine Biosynthesis PE(20:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))
- Phosphatidylethanolamine Biosynthesis PE(20:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))
- Phosphatidylethanolamine Biosynthesis PE(20:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))
- Phosphatidylethanolamine Biosynthesis PE(20:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))
- Phosphatidylethanolamine Biosynthesis PE(20:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))
- Phosphatidylethanolamine Biosynthesis PE(20:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))
- Phosphatidylethanolamine Biosynthesis PE(20:0/5-iso PGF2VI)
- Phosphatidylethanolamine Biosynthesis PE(20:0/6 keto-PGF1alpha)
- Phosphatidylethanolamine Biosynthesis PE(20:0/LTE4)
- Phosphatidylethanolamine Biosynthesis PE(20:0/PGD1)
- Phosphatidylethanolamine Biosynthesis PE(20:0/PGD2)
- Phosphatidylethanolamine Biosynthesis PE(20:0/PGE1)
- Phosphatidylethanolamine Biosynthesis PE(20:0/PGE2)
- Phosphatidylethanolamine Biosynthesis PE(20:0/PGF1alpha)
- Phosphatidylethanolamine Biosynthesis PE(20:0/PGF2alpha)
- Phosphatidylethanolamine Biosynthesis PE(20:0/PGJ2)
- Phosphatidylethanolamine Biosynthesis PE(20:0/TXB2)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,11Z,14Z)-O(8,9)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,11Z,14Z)-O(8,9)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,11Z,14Z)-O(8,9)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,11Z,14Z)-O(8,9)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,11Z,14Z)-O(8,9)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,11Z,14Z)-O(8,9)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)-O(14R,15S)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)-O(14R,15S)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)-O(14R,15S)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)-O(14R,15S)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)-O(14R,15S)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)-O(14R,15S)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,14Z)-O(11S,12R)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,14Z)-O(11S,12R)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,14Z)-O(11S,12R)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,14Z)-O(11S,12R)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,14Z)-O(11S,12R)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,14Z)-O(11S,12R)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(6,8,11)-OH(5)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(6,8,11)-OH(5)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(6,8,11)-OH(5)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(6,8,11)-OH(5)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(6,8,11)-OH(5)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(6,8,11)-OH(5)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-2OH(5,6)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-2OH(5,6)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-2OH(5,6)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-2OH(5,6)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-2OH(5,6)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-2OH(5,6)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-O(5,6)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-O(5,6)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-O(5,6)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-O(5,6)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-O(5,6)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)-O(5,6)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5E,8Z,12Z,14Z)-OH(11R)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5E,8Z,12Z,14Z)-OH(11R)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5E,8Z,12Z,14Z)-OH(11R)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5E,8Z,12Z,14Z)-OH(11R)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5E,8Z,12Z,14Z)-OH(11R)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5E,8Z,12Z,14Z)-OH(11R)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,7E,11Z,14Z)-OH(9)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,7E,11Z,14Z)-OH(9)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,7E,11Z,14Z)-OH(9)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,7E,11Z,14Z)-OH(9)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,7E,11Z,14Z)-OH(9)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,7E,11Z,14Z)-OH(9)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,10E,14Z)-OH(12S)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,10E,14Z)-OH(12S)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,10E,14Z)-OH(12S)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,10E,14Z)-OH(12S)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,10E,14Z)-OH(12S)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,10E,14Z)-OH(12S)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)+=O(15)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)+=O(15)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)+=O(15)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)+=O(15)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)+=O(15)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)+=O(15)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)-OH(15S)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)-OH(15S)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)-OH(15S)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)-OH(15S)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)-OH(15S)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,13E)-OH(15S)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(16R)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(16R)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(16R)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(16R)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(16R)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(16R)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(17)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(17)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(17)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(17)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(17)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(17)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(18R)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(18R)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(18R)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(18R)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(18R)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(18R)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(19S)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(19S)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(19S)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(19S)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(19S)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(19S)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(20)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(20)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(20)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(20)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(20)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)-OH(20)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)+=O(5)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)+=O(5)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)+=O(5)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)+=O(5)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)+=O(5)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)+=O(5)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)-OH(5S)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)-OH(5S)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)-OH(5S)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)-OH(5S)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)-OH(5S)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6E,8Z,11Z,14Z)-OH(5S)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(22:0/18:1(12Z)-2OH(9,10))
- Phosphatidylethanolamine Biosynthesis PE(22:0/18:1(12Z)-O(9S,10R))
- Phosphatidylethanolamine Biosynthesis PE(22:0/18:1(9Z)-O(12,13))
- Phosphatidylethanolamine Biosynthesis PE(22:0/18:2(10E,12Z)+=O(9))
- Phosphatidylethanolamine Biosynthesis PE(22:0/18:2(9Z,11E)+=O(13))
- Phosphatidylethanolamine Biosynthesis PE(22:0/18:3(10,12,15)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(22:0/18:3(9,11,15)-OH(13))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:3(5Z,11Z,14Z)-O(8,9))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:3(5Z,8Z,11Z)-O(14R,15S))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:3(5Z,8Z,14Z)-O(11S,12R))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:3(6,8,11)-OH(5))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:3(8Z,11Z,14Z)-2OH(5,6))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:3(8Z,11Z,14Z)-O(5,6))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5E,8Z,12Z,14Z)-OH(11R))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,7E,11Z,14Z)-OH(9))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,8Z,10E,14Z)-OH(12S))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,8Z,11Z,13E)+=O(15))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,8Z,11Z,13E)-OH(15S))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,8Z,11Z,14Z)-OH(17))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,8Z,11Z,14Z)-OH(20))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(6E,8Z,11Z,14Z)+=O(5))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(6E,8Z,11Z,14Z)-OH(5S))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))
- Phosphatidylethanolamine Biosynthesis PE(22:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
- Phosphatidylethanolamine Biosynthesis PE(22:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))
- Phosphatidylethanolamine Biosynthesis PE(22:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))
- Phosphatidylethanolamine Biosynthesis PE(22:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))
- Phosphatidylethanolamine Biosynthesis PE(22:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))
- Phosphatidylethanolamine Biosynthesis PE(22:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))
- Phosphatidylethanolamine Biosynthesis PE(22:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))
- Phosphatidylethanolamine Biosynthesis PE(22:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))
- Phosphatidylethanolamine Biosynthesis PE(22:0/5-iso PGF2VI)
- Phosphatidylethanolamine Biosynthesis PE(22:0/LTE4)
- Phosphatidylethanolamine Biosynthesis PE(22:0/PGD1)
- Phosphatidylethanolamine Biosynthesis PE(22:0/PGD2)
- Phosphatidylethanolamine Biosynthesis PE(22:0/PGE1)
- Phosphatidylethanolamine Biosynthesis PE(22:0/PGE2)
- Phosphatidylethanolamine Biosynthesis PE(22:0/PGF1alpha)
- Phosphatidylethanolamine Biosynthesis PE(22:0/PGF2alpha)
- Phosphatidylethanolamine Biosynthesis PE(22:0/PGJ2)
- Phosphatidylethanolamine Biosynthesis PE(22:0/TXB2)
- Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/14:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/15:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/16:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/18:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/20:0)
- Phosphatidylethanolamine Biosynthesis PE(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:0)
- Phosphatidylethanolamine Biosynthesis PE(5-iso PGF2VI/14:0)
- Phosphatidylethanolamine Biosynthesis PE(5-iso PGF2VI/15:0)
- Phosphatidylethanolamine Biosynthesis PE(5-iso PGF2VI/16:0)
- Phosphatidylethanolamine Biosynthesis PE(5-iso PGF2VI/18:0)
- Phosphatidylethanolamine Biosynthesis PE(5-iso PGF2VI/20:0)
- Phosphatidylethanolamine Biosynthesis PE(5-iso PGF2VI/22:0)
- Phosphatidylethanolamine Biosynthesis PE(6 keto-PGF1alpha/14:0)
- Phosphatidylethanolamine Biosynthesis PE(6 keto-PGF1alpha/15:0)
- Phosphatidylethanolamine Biosynthesis PE(6 keto-PGF1alpha/16:0)
- Phosphatidylethanolamine Biosynthesis PE(6 keto-PGF1alpha/18:0)
- Phosphatidylethanolamine Biosynthesis PE(6 keto-PGF1alpha/20:0)
- Phosphatidylethanolamine Biosynthesis PE(6 keto-PGF1alpha/22:0)
- Phosphatidylethanolamine Biosynthesis PE(LTE4/14:0)
- Phosphatidylethanolamine Biosynthesis PE(LTE4/15:0)
- Phosphatidylethanolamine Biosynthesis PE(LTE4/16:0)
- Phosphatidylethanolamine Biosynthesis PE(LTE4/18:0)
- Phosphatidylethanolamine Biosynthesis PE(LTE4/20:0)
- Phosphatidylethanolamine Biosynthesis PE(LTE4/22:0)
- Phosphatidylethanolamine Biosynthesis PE(PGD1/14:0)
- Phosphatidylethanolamine Biosynthesis PE(PGD1/16:0)
- Phosphatidylethanolamine Biosynthesis PE(PGD1/18:0)
- Phosphatidylethanolamine Biosynthesis PE(PGD1/20:0)
- Phosphatidylethanolamine Biosynthesis PE(PGD1/22:0)
- Phosphatidylethanolamine Biosynthesis PE(PGD2/14:0)
- Phosphatidylethanolamine Biosynthesis PE(PGD2/15:0)
- Phosphatidylethanolamine Biosynthesis PE(PGD2/16:0)
- Phosphatidylethanolamine Biosynthesis PE(PGD2/18:0)
- Phosphatidylethanolamine Biosynthesis PE(PGD2/20:0)
- Phosphatidylethanolamine Biosynthesis PE(PGD2/22:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE1/14:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE1/15:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE1/16:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE1/18:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE1/20:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE1/22:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE2/14:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE2/15:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE2/16:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE2/18:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE2/20:0)
- Phosphatidylethanolamine Biosynthesis PE(PGE2/22:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF1alpha/14:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF1alpha/15:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF1alpha/16:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF1alpha/18:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF1alpha/20:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF1alpha/22:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF2alpha/14:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF2alpha/15:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF2alpha/16:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF2alpha/18:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF2alpha/20:0)
- Phosphatidylethanolamine Biosynthesis PE(PGF2alpha/22:0)
- Phosphatidylethanolamine Biosynthesis PE(PGJ2/14:0)
- Phosphatidylethanolamine Biosynthesis PE(PGJ2/15:0)
- Phosphatidylethanolamine Biosynthesis PE(PGJ2/16:0)
- Phosphatidylethanolamine Biosynthesis PE(PGJ2/18:0)
- Phosphatidylethanolamine Biosynthesis PE(PGJ2/20:0)
- Phosphatidylethanolamine Biosynthesis PE(PGJ2/22:0)
- Phosphatidylethanolamine Biosynthesis PE(TXB2/14:0)
- Phosphatidylethanolamine Biosynthesis PE(TXB2/15:0)
- Phosphatidylethanolamine Biosynthesis PE(TXB2/16:0)
- Phosphatidylethanolamine Biosynthesis PE(TXB2/18:0)
- Phosphatidylethanolamine Biosynthesis PE(TXB2/20:0)
- Phosphatidylethanolamine Biosynthesis PE(TXB2/22:0)
- Phospholipid Biosynthesis
- (
show more
show less
)
|
PW_C000097
HMDB0000150:
View Metabocard
|
Gluconolactone
Gluconolactone is a lactone or oxidized derivative of glucose. Gluconolactone is a polyhydroxy acid (PHA) that is capable of chelating metals and may also function by scavenging free radicals, thereby protecting skin from some of the damaging effects of UV radiation. Also used as a pheromone by the oriental cockroach.
|
Drug Metabolism Drug Action
|
|
PW_C000098
HMDB0000151:
View Metabocard
|
Estradiol
Estradiol is the most potent form of mammalian estrogenic steroids. Estradiol is produced in the ovaries. The ovary requires both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to produce sex steroids. LH stimulates the cells surrounding the follicle to produce progesterone and androgens. The androgens diffuse across the basement membrane to the granulosa cell layer, where, under the action of FSH, they are aromatized to estrogens, mainly estradiol. The ovary shows cyclical activity, unlike the testis that is maintained in a more or less constant state of activity. Hormone secretions vary according to the phase of the menstrual cycle. In the developing follicle LH receptors (LH-R) are only located on the thecal cells and FSH receptors (FSHR) on the granulosa cells. The dominant pre-ovulatory follicle develops LH-Rs on the granulosa cells prior to the LH surge. Thecal cells of the preovulatory follicle also develop the capacity to synthesize estradiol and this persists when the thecal cells become incorporated into the corpus luteum. After ovulation, the empty follicle is remodelled and plays an important role in the second half or luteal phase of the menstrual cycle. This phase is dominated by progesterone and, to a lesser extent, estradiol secretion by the corpus luteum. estradiol is also synthesized locally from cholesterol through testosterone in the hippocampus and acts rapidly to modulate neuronal synaptic plasticity. Localization of estrogen receptor alpha (ERalpha) in spines in addition to nuclei of principal neurons implies that synaptic ERalpha is responsible for rapid modulation of synaptic plasticity by endogenous estradiol. estradiol is a potent endogenous antioxidant which suppresses hepatic fibrosis in animal models, and attenuates induction of redox sensitive transcription factors, hepatocyte apoptosis and hepatic stellate cells activation by inhibiting a generation of reactive oxygen species in primary cultures. This suggests that the greater progression of hepatic fibrosis and hepatocellular carcinoma in men and postmenopausal women may be due, at least in part, to lower production of estradiol and a reduced response to the action of estradiol. estradiol has been reported to induce the production of interferon (INF)-gamma in lymphocytes, and augments an antigen-specific primary antibody response in human peripheral blood mononuclear cells. IFN-gamma is a potent cytokine with immunomodulatory and antiproliferative properties. Therefore, female subjects, particularly before menopause, may produce antibodies against hepatitis B virus e antigen and hepatitis B virus surface antigen at a higher frequency than males with chronic hepatitis B virus infection. The estradiol-Dihydrotestosterone model of prostate cancer (PC) proposes that the first step in the development of most PC and breast cancer (BC) occurs when aromatase converts testosterone to estradiol. (PMID: 17708600, 17678531, 17644764).
|
Drug Metabolism Drug Action
|
|
PW_C000100
HMDB0000153:
View Metabocard
|
Estriol
Estriol is a metabolite of estrone metabolized via 16alpha-hydroxyestrone through the enzyme 16alpha-hydroxysteroid dehydrogenase (EC 1.1.1.147) or to 2- or 4-hydroxyestrone (catechol estrogens) by the action of catecho-O-methyltransferase (EC 2.1.1.6). The latter metabolites can be formed in the brain and may compete with receptors for catecholamines. Metabolites are conjugated with sulfate or glucuronide before excretion by the kidney. During pregnancy, estriol constitutes 60-70% of the total estrogens, increasing to 300-500-fold in relation to non-pregnant women. The late term human fetus produces relatively large amounts of 16 alphahydroxy DHEA, which serves the mother as a precursor of estriol. It has been shown that 90% of the precursors for the formation of estriol are of fetal origin. If abnormal maternal serum screening results, specifically low levels of unconjugated estriol in the second trimester are detected, a diagnosis of Smith-Lemli-Opitz syndrome (SLOS),or RSH is suspected. SLOS is an autosomal recessive disorder caused by mutations of the gene encoding 7-dehydrocholesterol reductase (EC 1.3.1.21, DHCR7). (PMID: 16202579, 16112271, 16097001).
|
Drug Metabolism Drug Action
|
|
PW_C000101
HMDB0000156:
View Metabocard
|
L-Malic acid
Malic acid is a tart-tasting organic dicarboxylic acid that plays a role in many sour or tart foods. Apples contain malic acid, which contributes to the sourness of a green apple. Malic acid can make a wine taste tart, although the amount decreases with increasing fruit ripeness. (wikipedia). In its ionized form malic acid is called malate. Malate is an intermediate of the TCA cycle along with fumarate. It can also be formed from pyruvate as one of the anaplerotic reactions. In humans, malic acid is both derived from food sources and synthesized in the body through the citric acid cycle or Krebs cycle which takes place in the mitochondria. Malate's importance to the production of energy in the body during both aerobic and anaerobic conditions is well established. Under aerobic conditions, the oxidation of malate to oxaloacetate provides reducing equivalents to the mitochondria through the malate-aspartate redox shuttle. During anaerobic conditions, where a buildup of excess of reducing equivalents inhibits glycolysis, malic acid's simultaneous reduction to succinate and oxidation to oxaloacetate is capable of removing the accumulating reducing equivalents. This allows malic acid to reverse hypoxia's inhibition of glycolysis and energy production. In studies on rats it has been found that only tissue malate is depleted following exhaustive physical activity. Other key metabolites from the citric acid cycle needed for energy production were found to be unchanged. Because of this, a deficiency of malic acid has been hypothesized to be a major cause of physical exhaustion. Notably, the administration of malic acid to rats has been shown to elevate mitochondrial malate and increase mitochondrial respiration and energy production.
|
Drug Metabolism Drug Action
|
|
PW_C000102
HMDB0000157:
View Metabocard
|
Hypoxanthine
Hypoxanthine is a naturally occurring purine derivative and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway. Hypoxanthine is also a spontaneous deamination product of adenine. Lesch-Nyhan disease is caused by deficiency of the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase. (OMIN 308000).
|
Drug Metabolism Drug Action
|
|
PW_C000103
HMDB0000158:
View Metabocard
|
L-Tyrosine
Tyrosine is an essential amino acid that readily passes the blood-brain barrier. Once in the brain, it is a precursor for the neurotransmitters dopamine, norepinephrine and epinephrine, better known as adrenalin. These neurotransmitters are an important part of the body's sympathetic nervous system, and their concentrations in the body and brain are directly dependent upon dietary tyrosine. Tyrosine is not found in large concentrations throughout the body, probably because it is rapidly metabolized. Folic acid, copper and vitamin C are cofactor nutrients of these reactions. Tyrosine is also the precursor for hormones, thyroid, catecholestrogens and the major human pigment, melanin. Tyrosine is an important amino acid in many proteins, peptides and even enkephalins, the body's natural pain reliever. Valine and other branched amino acids, and possibly tryptophan and phenylalanine may reduce tyrosine absorption. A number of genetic errors of tyrosine metabolism occur. Most common is the increased amount of tyrosine in the blood of premature infants, which is marked by decreased motor activity, lethargy and poor feeding. Infection and intellectual deficits may occur. Vitamin C supplements reverse the disease. Some adults also develop elevated tyrosine in their blood. This indicates a need for more vitamin C. More tyrosine is needed under stress, and tyrosine supplements prevent the stress-induced depletion of norepinephrine and can cure biochemical depression. However, tyrosine may not be good for psychosis. Many antipsychotic medications apparently function by inhibiting tyrosine metabolism. L-dopa, which is directly used in Parkinson's, is made from tyrosine. Tyrosine, the nutrient, can be used as an adjunct in the treatment of Parkinson's. Peripheral metabolism of tyrosine necessitates large doses of tyrosine, however, compared to L-dopa. (http://www.dcnutrition.com).
|
Drug Metabolism Drug Action
|
|
PW_C000104
HMDB0000159:
View Metabocard
|
L-Phenylalanine
Phenylalanine is an essential amino acid and the precursor of the amino acid tyrosine. Like tyrosine, phenylalanine is also a precursor for catecholamines including tyramine, dopamine, epinephrine, and norepinephrine. Catecholamines are neurotransmitters that act as adrenalin-like substances. Interestingly, several psychotropic drugs (mescaline, morphine, codeine, and papaverine) also have phenylalanine as a constituent. Phenylalanine is highly concentrated in the human brain and plasma. Normal metabolism of phenylalanine requires biopterin, iron, niacin, vitamin B6, copper, and vitamin C. An average adult ingests 5 g of phenylalanine per day and may optimally need up to 8 g daily. Phenylalanine is highly concentrated in a number of high protein foods, such as meat, cottage cheese, and wheat germ. An additional dietary source of phenylalanine is artificial sweeteners containing aspartame. As a general rule, aspartame should be avoided by phenylketonurics and pregnant women. When present in sufficiently high levels, phenylalanine can act as a neurotoxin and a metabotoxin. A neurotoxin is a compound that disrupts or attacks neural cells and neural tissue. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of phenylalanine are associated with at least five inborn errors of metabolism, including Hartnup disorder, hyperphenylalaninemia due to guanosine triphosphate cyclohydrolase deficiency, phenylketonuria (PKU), tyrosinemia type 2 (or Richner-Hanhart syndrome), and tyrosinemia type III (TYRO3). Phenylketonurics have elevated serum plasma levels of phenylalanine up to 400 times normal. High plasma concentrations of phenylalanine influence the blood-brain barrier transport of large neutral amino acids. The high plasma phenylalanine concentrations increase phenylalanine entry into the brain and restrict the entry of other large neutral amino acids (PMID: 19191004). Phenylalanine has been found to interfere with different cerebral enzyme systems. Untreated phenylketonuria (PKU) can lead to intellectual disability, seizures, behavioural problems, and mental disorders. It may also result in a musty smell and lighter skin. Classic PKU dramatically affects myelination and white matter tracts in untreated infants; this may be one major cause of neurological disorders associated with phenylketonuria. Mild phenylketonuria can act as an unsuspected cause of hyperactivity, learning problems, and other developmental problems in children. It has been recently suggested that PKU may resemble amyloid diseases, such as Alzheimer's disease and Parkinson's disease, due to the formation of toxic amyloid-like assemblies of phenylalanine (PMID: 22706200). Phenylalanine also has some potential benefits. Phenylalanine can act as an effective pain reliever. Its use in premenstrual syndrome and Parkinson's may enhance the effects of acupuncture and electric transcutaneous nerve stimulation (TENS). Phenylalanine and tyrosine, like L-DOPA, produce a catecholamine-like effect. Phenylalanine is better absorbed than tyrosine and may cause fewer headaches. Low phenylalanine diets have been prescribed for certain cancers with mixed results. For instance, some tumours use more phenylalanine than others (particularly melatonin-producing tumours called melanomas).
|
Drug Metabolism Drug Action
|
|
PW_C000105
HMDB0000161:
View Metabocard
|
L-Alanine
Alanine is a non-essential amino acid made in the body from either the conversion of the carbohydrate pyruvate or the breakdown of DNA and the dipeptides carnosine and anserine. It is highly concentrated in muscle and is one of the most important amino acids released by muscle, functioning as a major energy source. Plasma alanine is often decreased when the BCAA (branched-chain amino acids) are deficient. This finding may relate to muscle metabolism. Alanine is highly concentrated in meat products and other high-protein foods like wheat germ and cottage cheese. Alanine is an important participant as well as a regulator of glucose metabolism. Alanine levels parallel blood sugar levels in both diabetes and hypoglycemia, and alanine reduces both severe hypoglycemia and the ketosis of diabetes. It is an important amino acid for lymphocyte reproduction and immunity. Alanine therapy has helped dissolve kidney stones in experimental animals. Normal alanine metabolism, like that of other amino acids, is highly dependent upon enzymes that contain vitamin B6. Alanine, like GABA, taurine, and glycine, is an inhibitory neurotransmitter in the brain (http://www.dcnutrition.com/AminoAcids/). L-Alanine has been found to be associated with glucagon deficiency, which is an inborn error of metabolism.
|
Drug Metabolism Drug Action
|
|
PW_C000106
HMDB0000162:
View Metabocard
|
L-Proline
L-proline is one of the twenty amino acids used in living organisms as the building blocks of proteins. Proline is sometimes called an imino acid, although the IUPAC definition of an imine requires a carbon-nitrogen double bond. Proline is a non-essential amino acid that is synthesized from glutamic acid. It is an essential component of collagen and is important for proper functioning of joints and tendons. Proline is derived from the amino acid L-glutamate in which glutamate-5-semialdehyde is first formed by glutamate 5-kinase and glutamate-5-semialdehyde dehydrogenase (which requires NADH or NADPH). This semialdehyde can then either spontaneously cyclize to form 1-pyrroline-5-carboxylic acid, which is reduced to proline by pyrroline-5-carboxylate reductase, or turned into ornithine by ornithine aminotransferase, followed by cyclization by ornithine cyclodeaminase to form proline. L-Proline has been found to act as a weak agonist of the glycine receptor and of both NMDA and non-NMDA ionotropic glutamate receptors. It has been proposed to be a potential endogenous excitotoxin/neurotoxin. Studies in rats have shown that when injected into the brain, proline non-selectively destroys pyramidal and granule cells (PMID: 3409032). Therefore, under certain conditions proline can act as a neurotoxin and a metabotoxin. A neurotoxin causes damage to nerve cells and nerve tissues. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of proline are associated with at least five inborn errors of metabolism, including hyperprolinemia type I, hyperprolinemia type II, iminoglycinuria, prolinemia type II, and pyruvate carboxylase deficiency. People with hyperprolinemia type I often do not show any symptoms even though they have proline levels in their blood between 3 and 10 times the normal level. Some individuals with hyperprolinemia type I exhibit seizures, intellectual disability, or other neurological or psychiatric problems. Hyperprolinemia type II results in proline levels in the blood between 10 and 15 times higher than normal, and high levels of a related compound called pyrroline-5-carboxylate. Hyperprolinemia type II has signs and symptoms that vary in severity, and is more likely than type I to involve seizures or intellectual disability.
|
Drug Metabolism Drug Action
|
|
PW_C000107
HMDB0000163:
View Metabocard
|
D-Maltose
Maltose, or malt sugar, is a primary disaccharide in the human diet formed from two units of glucose joined with an alpha (1->4) linkage. It is the second member of an important biochemical series of glucose chains. The addition of another glucose unit yields maltotriose, Further additions will produce dextrins, also called maltodextrins, and eventually starch. Maltose can be broken down into two glucose molecules by hydrolysis in living organisms. At the surface of the small intestine, the brush border enzymes maltase, breaks down maltose. (PMID: 14522745).
|
Drug Metabolism Drug Action
|
- Glycogen Synthetase Deficiency
- Glycogen Synthetase Deficiency
- Glycogenosis, Type III. Cori Disease, Debrancher Glycogenosis
- Glycogenosis, Type III. Cori Disease, Debrancher Glycogenosis
- Glycogenosis, Type IV. Amylopectinosis, Anderson Disease
- Glycogenosis, Type IV. Amylopectinosis, Anderson Disease
- Glycogenosis, Type VI. Hers Disease
- Glycogenosis, Type VI. Hers Disease
- Mucopolysaccharidosis VII. Sly Syndrome
- Mucopolysaccharidosis VII. Sly Syndrome
- Starch and Sucrose Metabolism
- Sucrase-Isomaltase Deficiency
- Sucrase-Isomaltase Deficiency
- (
show more
show less
)
|